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Dendritic cells (DC) are professional antigen-presenting cells that play a pivotal role in the induction of immunity. Ex vivo-generated,
tumour antigen-loaded mature DC are currently exploited as cancer vaccines in clinical studies. However, antigen loading and
maturation of DC directly in vivo would greatly facilitate the application of DC-based vaccines. We formerly showed in murine models
that radiofrequency-mediated tumour destruction can provide an antigen source for the in vivo induction of anti-tumour immunity,
and we explored the role of DC herein. In this paper we evaluate radiofrequency and cryo ablation for their ability to provide an
antigen source for DC and compare this with an ex vivo-loaded DC vaccine. The data obtained with model antigens demonstrate that
upon tumour destruction by radiofrequency ablation, up to 7% of the total draining lymph node (LN) DC contained antigen, whereas
only few DC from the conventional vaccine reached the LN. Interestingly, following cryo ablation the amount of antigen-loaded DC is
almost doubled. Analysis of surface markers revealed that both destruction methods were able to induce DC maturation. Finally, we
show that in situ tumour ablation can be efficiently combined with immune modulation by anti-CTLA-4 antibodies or regulatory T-
cell depletion. These combination treatments protected mice from the outgrowth of tumour challenges, and led to in vivo
enhancement of tumour-specific T-cell numbers, which produced more IFN-g upon activation. Therefore, in situ tumour destruction
in combination with immune modulation creates a unique, ‘in situ DC-vaccine’ that is readily applicable in the clinic without prior
knowledge of tumour antigens.
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Dendritic cells (DC) are crucial antigen-presenting cells (APC) for
the initiation of primary T-cell responses (Adams et al, 2005;
Banchereau and Palucka, 2005). Immature DC are well equipped to
take up and process antigen from their surroundings, but they lack
sufficient co-stimulatory signals required for productive T-cell
activation. In a stimulatory environment, like in an infection,
immature DC undergo activation, maturation and acquire the
capacity to cross-present exogenous antigens in MHC class I.
Particularly, the Toll-like receptor (TLR) family of proteins initiates
the DC maturation process upon recognition of conserved
pathogen-associated molecular patterns (PAMPs), like LPS or
unmethylated CpG oligodeoxynucleotides. Upon maturation, co-
stimulatory molecule and MHC-peptide complex expression
increases and cytokines like IL-12 skew the functional outcome of
the response (Trinchieri, 2003). Dendritic cells that did not perceive
an activating environment while taking up antigen do not mature
and induce tolerance rather than immunity. The importance of
immune activation for the induction of anti-tumour immunity has
been well established. Next to direct activation of DC by PAMPs, a
broad range of indirect strategies has been explored to accomplish
activation of the immune system. Expression of, for instance, co-
stimulatory molecules on tumours can induce T-cell-mediated
rejection of a variety of tumours (Townsend and Allison, 1993). In
addition to these stimulatory pathways, also blockade of inhibitory
receptors, for example, CTLA-4, has been applied successfully to
induce tumour rejection (Chen et al, 1992; Egen et al, 2002). In this
respect, also in vivo depletion of regulatory T cells, that are able to
suppress conventional T-cell expansion, has been shown to evoke
anti-tumour immunity (Sutmuller et al, 2001; Sakaguchi, 2005).
As murine models demonstrate that especially DC are effective
in inducing effective immune responses, ex vivo generated DC are
currently applied to stimulate anti-tumour immunity in clinical
trials (Banchereau et al, 2000; Coulie and van der Bruggen, 2003;
De Vries et al, 2003; Schuler et al, 2003; Figdor et al, 2004).
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sAlthough tumour-specific responses have been obtained with
tumour antigen-loaded DC-based vaccines, many questions
remain unanswered (Figdor et al, 2004; Steinman and Mellman,
2004). Especially the migration of ex vivo generated DC-based
vaccines from i.d./subcutaneously (s.c.) injected depots to the
draining lymph nodes (LN) has been shown to be inefficient in
both mouse models and patients (Eggert et al, 1999; Josien et al,
2000; De Vries et al, 2003). Moreover, ex vivo generation and
loading of DC is time consuming and costly. In vivo loading and
maturation of DC would therefore improve the applicability of DC
vaccination to a great extend.
Recent studies using antigens coupled to antibodies directed
against the mouse DC antigen DEC-205 (Steinman and Pope, 2002)
or attraction of DC to the tumour via retrovirus-mediated
expression of the DC-attracting chemokine CCL20 (Furumoto
et al, 2004) illustrate the possibility to directly load tumour
antigens onto DC in vivo. We previously showed in a murine
model that the tumour debris left in the body after in situ tumour
destruction by radiofrequency ablation is an in vivo tumour
antigen source for the immune system. Excision of the ablated
tumour largely prevented the induction of anti-tumour immunity
(unpublished observation). Adoptive transfer experiments demon-
strated that the immunity induced is T-cell-dependent. Dendritic
cells appeared to play an important role in the initiation of this
immune response. Tumour ablative treatments, like cryo or
radiofrequency ablation, are successfully used in clinical settings
to destruct different types of tumours (Zagoria et al, 2001; Ruers
and Bleichrodt, 2002; Curley, 2003; Garcea et al, 2003; Raj et al,
2003). Nevertheless, cancer patients treated with ablative regimens
mostly develop systemic recurrences as a consequence of the
outgrowth of distant micro-metastases, implying that in general no
protective immune response is induced. This observation is
consistent with our findings that efficient induction of immunity
following ablation requires that additional immune activation
stimuli are given simultaneously (den Brok et al, 2004).
We now show that in situ tumour destruction by either cryo or
radiofrequency ablation can be employed to efficiently provide
antigens to DC in vivo. A side-by-side comparison of the two
ablative techniques demonstrates that following cryo ablation of
established B16 tumours (5–7mm) up to 13% of DC in the
draining LN acquire tracer proteins as a marker of tumour-derived
antigen. Radiofrequency ablation results in 7% of LN DC being
loaded with the marker antigen. With both ablation methods far
more marker antigen-containing DC are detected in the draining
LN than with a conventional in vitro generated DC vaccine. We
further show that both destruction methods in itself were able to
enhance DC maturation in vivo to an equal extend, comparable to
ex vivo maturation of DC. Finally, we report that both tumour
ablation techniques can be efficiently combined with immuno-
modulatory approaches, like blockade of CTLA-4 signalling or
regulatory T-cell depletion, to induce functional CD8þ T cells
creating systemic anti-tumour-immunity.
Therefore, in situ tumour destruction by cryo or radiofrequency
ablation combined with immuno-modulatory approaches consti-
tutes a powerful ‘in situ DC-vaccine’ for which no prior knowledge
of tumour antigens is needed.
MATERIALS AND METHODS
Animals
Nine- to 11-week-old female C57BL/6n mice were purchased from
Charles River Wiga (Sulzfeld, Germany). Animals were held under
specified pathogen-free conditions in the Central Animal Labora-
tory (Nijmegen, The Netherlands). All experiments were per-
formed according to the guidelines for animal care of the Nijmegen
Animal Experiments Committee.
Tumours
Mice were injected s.c. at the right femur with 500 10
3 cells of the
OVA-transfected murine melanoma cell line B16F10 (B16-OVA,
clone MO5), which was kindly provided by Dr Kenneth Rock (Falo
et al, 1995), or wt B16F10. Cells were cultured and injected as
described before (den Brok et al, 2004). Tumour volumes were
scored every 3 days with the formula (AxB
2) 0.4, in which A is
the largest and B is the shortest dimension. Tumours were selected
for ablation when their diameter measured between 5 and 7mm
(d9–10) and only if the tumour was relatively round (498% of
mice).
Radiofrequency ablation
Animals were anaesthetised by isoflurane inhalation and properly
shaved at the tumour area and on the contra-lateral flank. After
placement and proper attachment of the contra lateral side onto an
electricity-conducting pad (grounding pad), the tumour area was
disinfected with alcohol. A radiofrequency ablation needle with
active tip of 8mm (SMK-15, Cotop, Amsterdam, The Netherlands)
was inserted s.c. and placed in the middle of the tumour. After
placement of the radiofrequency ablation needle, impedance could
be evaluated on the radiofrequency lesion generator system (Model
RFG-3B, Radionics, Burlington, MA, USA). Next, treatment was
started by delivering radiofrequency energy. During a treatment
cycle of 780s, temperature could be monitored by means of a
thermistor and thermocouple in the tip of the probe. Treatment
was considered successful if a tip temperature of 75–801C could be
reached.
Cryo ablation
Animals were properly shaven and anaesthetised by isoflurane
inhalation. The tumour area was disinfected with alcohol and
subsequently wetted with distilled water. The tip of the liquid
nitrogen cryo ablation system (CS76, Frigitronics, Shelton, CT,
USA) was placed onto the tumour and after proper freeze
attachment, treatment was started. During two treatment cycles
of 770s the tumour and a small strip around it were frozen to less
than  1001C. Treatment was considered successful when the whole
tumour appeared frozen macroscopically.
Re-challenge model
Forty days after ablation of B16-OVA tumours, mice were
challenged by s.c. injection at the contra-lateral femur of either
15 10
3 B16-OVA cells or 15 10
3 EL4 cells (numbers defined by
titration). Injections were performed in 100ml PBS. Mice were
killed when tumours reached a volume of 7850mm
3.
111Indium conjugation and antigen monitoring
KLH (Calbiochem, Darmstadt, Germany) (10mgml
 1) was con-
jugated with 240mg cDTPA (Sigma-Aldrich, Zwijndrecht, The
Netherlands) in 0.1 M NaHCO3, pH 8.2, during 30min. Unconju-
gated DTPA was removed by dialysis against 0.1 M Na-citrate
buffer, pH 5.0. The KLH-DTPA conjugate (1.5mg) was incubated
with 1.5mCi
111InCl3 (Mallinckrodt, Petten, The Netherlands) in
1.2ml 0.1 M Na-citrate buffer, pH 5.0, during 30min. Similar
procedures were followed for the
111In-OVA conjugate. Radio-
chemical purity of each preparation (495%) was determined by
instant thin-layer chromatography (ITLC, Gelman Sciences Inc.,
MI, USA). For antigen monitoring experiments, mice received
intratumoural (i.t.) injections of OVA/KLH labelled with
111In
(
111In-OVA,
111In-KLH) or ovalbumin conjugated to Alexa-488
(OVA-Alexa-488) (Molecular Probes, Leiden, The Netherlands).
Conjugates (20mg( ¼20mCi)) were injected directly before
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protein conjugates, mice were anesthetised and scintigraphic
images were acquired using a g-camera with
111In collimator
(Siemens Orbiter, Siemens Inc. Hoffmann Estate, IL, USA) as
described previously (Eggert et al, 1999). For biodistribution
studies mice were killed at different time points after injection of
the protein conjugates. Liver, kidney, spleen, draining LN (r. sup.
ing.) and non-draining LN (l. sup. ing.) were collected, weighed
and counted in a g-counter (1480 Wizard, Wallac Oy, Finland).
Injection standards were taken for physical decay correction. In
DC sorting experiments, mice received
111In-KLH i.t., and at
different time points post-ablation CD11cþ DC were sorted as
described below and counted in the g-counter.
Magnetic bead cell sorting and flow cytometric analysis
For antigen uptake experiments (
111In-KLH and OVA-Alexa),
draining LN’s from five to eight mice were pooled and after
crushing, dissociation in DNAse/collagenase/EDTA, and passage
through nylon mesh (Vremec et al, 2000), cells were counted and
sorted by standard MACS isolation with a MACS Midi column
(Miltenyi Biotec). Positive selection of DC was done using CD11c
beads (clone N418, Miltenyi Biotec, B.Gladbach, Germany),
whereas negative selection/enrichment was done on the CD90 T-
cell marker (Thy1.2, 30.H12, Miltenyi Biotec). Sorts were verified
by CD3e or CD11c (HL3) staining (not shown). Subsequently, cells
were stained and analysed on a FACS-Caliburt system (BD) with
the CELLQuest software. Stainings were performed using the
following mAbs: CD11c-APC (HL3), CD8b-FITC (53–5.8), CD3e-
PE (17-A2), biotinylated CD80 (1G10) and streptavidin-PE. All
antibodies were purchased from BD Pharmingen (Alphen a/d Rijn,
The Netherlands).
Dendritic cell culture from green fluorescent protein
transgenic mice
GFP-expressing DC were cultured and injected as described
elsewhere (Eggert et al, 2003). Briefly, bone marrow was collected
from GFP-transgenic mice and cultured for 7 days in the presence
of GM-CSF and IL-4. At day 7, 1mgml
 1 LPS was added for 24h
maturation. Next, the non-adherent fraction was harvested,
washed and loaded for 1h with the K
b-peptide of OVA
(SIINFEKL). Cells (1 10
6) were injected s.c. or peri-tumourally
(p.t.) at the femur. Isolation of LN cells and sorting was identical as
described above.
Antibody treatments
In the anti-CTLA-4 treatment mice received anti-CTLA-4 antibody
(clone 9H10 (Egen et al, 2002)) at days 0, 3 and 6 after ablation.
Treg depletion was performed by injection of anti-CD25 antibodies
(clone PC61, (Onizuka et al, 1999)) 4 days before ablation.
Injections (200mg) were done intraperitoneal in PBS. In all cases
depletion was successful as verified by FACS (not shown).
Tetramer staining and interferon-c measurement
A T-cell culture was obtained from spleen and draining LN’s of
mice 10 days after ablation of a B16-OVA tumour or from naı ¨ve
control mice. Stimulation of these cells (100 10
3) was performed
by addition of irradiated, IFN-g-treated, B16-OVA cells (50 10
3)
in IL-2 (10CUml
 1) supplemented culture medium. At days 5 and
10, cells were collected and cleaned in a density gradient. At day 10
of culture, cells were stained for 15min at RT by OVA-tetramers
(H-2K
b) conjugated to APC (Pelimers, Sanquin, Amsterdam, The
Netherlands), counterstained with CD8b, and analysed by FACS.
Same bulk cultures were used to collect supernatant 24h after
stimulation with irradiated B16-OVA cells. Capture and biotiny-
lated detection antibodies directed to mouse IFN-g were purchased
from BD Pharmingen and, using standard ELISA procedures, IFN-
g concentration was measured in 50ml of supernatant.
Statistical analysis
Data were analysed for statistical significance by Student’s t test,
except for the Kaplan–Meier survival curves for which a log rank
test was used.
RESULTS
Immune responses following radiofrequency or cryo
ablation
We previously demonstrated that radiofrequency ablation of
established (5–7mm) murine tumours resulted in weak, but
tumour-specific anti-tumour reactivity. However, the mechanism
by which immunity is induced and the role of DC herein remain
largely unknown. Therefore, we explored the fate of tumour debris
generated by two distinct tumour ablation approaches and the role
of DC in the subsequent induction of immune responses. To first
compare the induction of immunity after both techniques, B16-
OVA tumour-bearing mice were treated with either radiofrequency
or cryo ablation and then re-challenged with either B16-OVA cells
or non-related EL4 thymoma cells. A detailed time schedule is
given below Figure 1. Re-challenges were given 40 days after
ablation to exclude direct effects of the ablations on the tumour re-
challenge. As shown in Figure 1, radiofrequency ablation of B16-
OVA resulted in a clear delay in the outgrowth of B16-OVA
tumour cells as compared to naı ¨ve controls and a low level of
protection (20% of the mice, lower right panel). Interestingly,
when mice received cryo ablation, slightly more mice were
protected (50% of the mice, upper right panel). In contrast, no
delay in outgrowth of the non-related EL4 mouse thymoma was
observed (left panels). These data imply that a weak, but tumour-
specific immune response had developed after both in situ tumour
destruction techniques. In all experiments, cryo ablation was
slightly more effective than radiofrequency ablation.
Efficient in vivo antigen acquisition by lymph node
CD11c(þ) dendritic cell following ablation
To determine the fate of tumour antigens and the involvement of
DC in the observed anti-tumour immune responses, we studied in
vivo antigen acquisition by DC following radiofrequency and cryo
ablation. Mice carrying established B16-OVA tumours (5–7mm)
received an i.t. injection of
111Indium-labelled KLH or
111In-OVA
tracer proteins before ablation to monitor the fate of tumour-
debris. g-Camera imaging demonstrated that
111In proteins
remained in the tumour for at least 72h, whereas unbound
111InCl3 rapidly distributes throughout the mice (Figure 2A). Even
following both ablation procedures
111In-KLH and OVA largely
remained at the treated site whereas only minor local spreading
was observed. In case
111In-OVA was used slightly more spreading
to the liver was seen compared to KLH, which is likely dependent
on the molecular characteristics of OVA. Biodistribution analysis
revealed an ablation-dependent accumulation of radioactivity in
the draining LN’s when
111In-KLH (Figure 2B–D) or
111In-OVA
(not shown) was used. Although significantly different from
untreated tumour-bearing mice, radiofrequency-ablated mice
showed significantly less accumulation of radioactivity compared
to cryo ablation (Figure 2B). Little or no activity was found in the
non-draining LN’s, liver, kidneys or spleen with or without
ablation (Figure 2C), whereas the organs contained high concen-
trations of radioactivity following injection of unbound
111InCl3
(not shown).
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we analysed the cells in the draining LN’s containing
111In-KLH. As
shown in Figure 2D, following ablation the cell-associated radio-
activity was largely present in the CD11c(þ) fraction at 1 and even
3 days after ablation. Despite the fact that the CD11c(þ) DC only
comprised a minor fraction of total LN cells, they accounted for up
to 25% of total cell-associated activity present in the LN’s (cryo
ablation, not shown). Consistent with Figure 2B, uptake of
111In-
KLH following radiofrequency ablation was significantly lower
compared to cryo ablation. The counts in the CD11c( ) fractions
were all below 100 (not shown).
These data obtained using marker model antigens thus strongly
suggest that also tumour-debris created by ablation acts as an
antigen depot and that released antigens preferentially accumulate
in CD11c(þ) DC in the draining LN. They also show that the
method of destructing a tumour is highly relevant for the
subsequent uptake dynamics of antigens.
Accumulation of antigen-positive lymph node dendritic
cell following ablation or conventional dendritic cell
vaccination
To compare the in vivo loading of DC by ablation with an
externally loaded conventional DC vaccine, we analysed the
numbers of antigen-positive LN DC after performing both
techniques. In order to trace the antigen-experienced DC by
flowcytometry, ovalbumin conjugated to the fluorophore Alexa-
488 (OVA-Alexa) was injected i.t. before ablation and DC derived
from GFP-transgenic mice were used as an ex vivo DC vaccine.
These GFP DC were matured with LPS, loaded with the relevant
OVA-K
b peptide (SIINFEKL) and 1 10
6 DC were next injected s.c.
or around an established (5–7mm) B16-OVA tumour (p.t.). As
shown in Figure 3A, over 12% of all draining LN CD11c(þ)D C
became OVA-Alexa(þ) after cryo ablation, whereas after radio-
frequency ablation 7% of DC acquired the antigen. These data are
in line with the accumulation of antigens in DC observed with
111In-proteins (see also Figure 2). Consistent with other studies
(Josien et al, 2000; De Vries et al, 2003; Eggert et al, 2003), only
small numbers (o1%) of the ex vivo generated GFP DC reached
the draining LN (Figure 3B). Moreover, plotting the absolute
numbers of DC present in the draining LN further revealed a
significant increase in total DC numbers after ablation, accom-
panied by an increased LN volume (Figure 3C and not shown).
This implies that the absolute number of DC actually loaded with
tumour antigen is even higher than can be concluded from the
relative percentages of antigen-loaded DC shown in Figure 3A.
These data thus indicate that ablation is far more effective in
obtaining marker antigen-loaded DC in the draining LN as
compared to conventional DC vaccination.
Ablation-dependent maturation of antigen-positive lymph
node dendritic cell
Next, we studied the maturation of DC in relation to antigen
uptake. Therefore, OVA-Alexa(þ) or OVA-Alexa( ) (in vaccina-
tion: GFP(þ)o r(  )) DC were analysed for expression of the DC
maturation marker CD80. OVA-Alexa(þ) DC showed a three-fold
increase in CD80 expression relative to OVA-Alexa( )D Ci n
tumour-bearing and naı ¨ve mice (MFI’s 987, 318 and 310,
respectively) (Figure 4A). Moreover, CD80 expression further
increased following cryo or radiofrequency ablation on OVA-
Alexa(þ) DC but had no effect on OVA-Alexa( ) DC (MFI 1690
vs 362 and 1567 vs 361, respectively). This indicates that DC that
acquired OVA-Alexa, as an indicator of tumour-debris, preferen-
tially upregulate CD80, whereas this effect is further enhanced by
ablation. Importantly, the induction of maturation by radio-
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Figure 1 Anti-tumour immunity following radiofrequency or cryo ablation. Mice with established B16-OVA melanomas (5–7mm) were ablated by cryo
(cryo, upper panels) or radiofrequency ablation (RF, lower panels). Forty days later, a re-challenge with 15 10
3 EL4 (left panels) or 15 10
3 B16-OVA cells
(right panels) was given s.c. in the contra-lateral leg. Figures depict survival curves demonstrating specificity of the response and growth reduction/protection
after ablation. As a control, tumour growth was monitored by injection of the same tumour dose into naı ¨ve mice (dotted lines). T¼0 corresponds to the
time of injection of the tumour re-challenge. Po0.005 for both B16 lines vs control. One out of four representative experiments is shown (n¼5–11).
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sfrequency ablation is equal to the induction by cryo ablation, even
though less antigen uptake was observed. Analysis of the GFP-DC
in the LN for CD80 expression, demonstrated that the exogenously
loaded GFP(þ) DC were significantly more mature than the
resident endogenous GFP( ) DC (Figure 4B) The observed MFI’s
were comparable to those seen on antigen-positive DC after
ablation and were similar after p.t. or s.c. injection (Figure 4B).
Similar, but somewhat less profound results were obtained with
CD86 expression (not shown).
The combined data thus not only indicate that ablation
results in efficient DC loading but also that ablation-induced
CD80 expression of the OVA-Alexa(þ) DC in the LN equals the
CD80 expression on the DC from the LPS-matured ex vivo DC
vaccine.
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Figure 2 Preferential uptake of tumour-derived antigens by LN DCs. (A) To study the fate of tumour antigens after ablation, 20mCi of
111In-Cl3 (left
panel),
111In-KLH (middle panels) or
111In-OVA (right panels) was injected into established B16-OVA tumours (5–7mm). Tumours were left untreated or
ablated by cryo ablation (cryo) or radiofrequency ablation (RF) directly after these injections. g-Camera imaging was performed at the indicated time points.
For
111In-Cl3-injected mice the contours, tumour and liver are visible. One representative mouse out of three is shown. (B and C) Biodistribution of
111In-
KLH was determined in dissected LNs and organs of mice injected i.t. 1 day before. Tumours were either left untreated or ablated directly after KLH
injection. Radioactivity values from LN’s of four mice per group are presented as mean percentages of injected dose with s.d., whereas the values for the
organs are also corrected for weight. Mice in panel C received cryo ablation, but comparable results were obtained with RF ablation. (D) Lymph node
suspensions from non-ablated and ablated mice (five mice pooled per group) that received i.t.
111In-KLH were subjected to magnetic bead sorting of
CD11c(þ) cells. After sorting at days 1 and 3 after ablation, the cell-associated radioactivity was measured in the CD11c(þ) and CD11c( ) (not shown)
cell fraction. Values are presented as counts per minute, corrected for 1 10
6 cells and natural decay, with s.d. from triplicates. *¼Po0.005 compared to
no ablation. In all figures one out of three representative experiments is shown.
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sCTLA-4 blockade following ablation enhances systemic
anti-tumour immunity
We previously showed that immune modulation by blockade of
CTLA-4 signalling enhances anti-tumour immunity after radio-
frequency ablation. We now studied whether CTLA-4 blockade
could be also used in the cryo ablation model. Figure 5 shows that
the weak anti-tumour response observed after cryo ablation alone
indeed could be enhanced by combination with CTLA-4 blockade.
Comparable results were obtained when radiofrequency ablation
was applied (Figure 5A). Control experiments showed that CTLA-4
injection alone had no significant effect on primary tumours or re-
challenges (Figure 5B, left and right panel, respectively). Analysis
of the mice for OVA-specific T cells revealed that far more specific
T cells were present 10 days after the combination treatment as
compared to ablation alone (Figure 5C). To determine the
activation status of these T cells, IFN-g production was measured
after activation with B16-OVA cells. Interestingly, T cells derived
from mice treated with anti-CTLA-4 and ablation showed
increased IFN-g production upon recognition of antigen compared
to the IgG treatment (Figure 5D). In correspondence with the re-
challenge model, somewhat less IFN-g producing, specific T cells
were detected after radiofrequency ablation than after cryo
ablation.
Depletion of regulatory T cells before ablation enhances
systemic anti-tumour immunity
Next, we investigated whether depletion of regulatory T cells
before ablation was also able to enhance tumour immunity.
Hereto, mice received anti-CD25 antibodies 4 days before ablation
of their B16-OVA tumours. The anti-CD25 antibodies did not have
any effect on the outgrowth of the B16-OVA tumours, yielding
similar tumour-sizes at the day of ablation (see also Figure 6B).
Figure 6A shows that Treg depletion enhances the initially weak
anti-tumour responses after both ablative techniques. This effect is
comparable to the effects seen with anti-CTLA-4 treatment (see
also Figure 5). Treg depletion alone had no significant effect on
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Figure 3 Increased numbers of antigen-positive DC in draining LN following ablation. (A) Fluorescence-activated cell sorting analysis of CD11c(þ)D C
isolated from pooled LN suspensions of naı ¨ve, tumour-bearing or tumour-ablated mice (n¼6 per group). Mice received 20mg ovalbumin conjugated to
Alexa-488 (OVA-Alexa488) i.t. just before the time point of ablation. Two days after the indicated treatments, CD11c(þ) DC were isolated from draining
LNs, stained for CD11c (clone HL3), gated and plotted for OVA-Alexa488 content. Values shown are percentages of OVA-Alexa488(þ) cells within the
CD11c(þ) fraction. (B) Bone marrow dendritic cells were cultured from GFP-transgenic mice, loaded with peptides and matured ex vivo with LPS.
Dendritic cells (1 10
6 ) were injected p.t. in tumour-bearing mice or s.c. into naı ¨ve mice. Two days later CD11c(þ) DC were isolated from pooled LN
suspensions (n¼6 per group), stained, gated and plotted for GFP. (C) Absolute CD11c(þ) cell count per LN. Data are obtained from experiments
described in A and B and presented as means with s.d. from three independent experiments. As controls for all experiments, naı ¨ve mice were used that did
not receive any injection (naı ¨ve). *¼Po0.005 vs naı ¨ve, **¼Po0.01 both vs no ablation.
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sprimary tumours or re-challenges (Figure 6B). Tetramer analysis
confirmed the presence of IFN-g producing, tumour-specific T
cells after the combination treatment, whereas after each
individual treatment these cells were absent (Figure 6C and D).
In correspondence with the re-challenge model, somewhat less
specific T cells were detected after radiofrequency ablation then
after cryo ablation.
Collectively, these data thus suggest that antigen uptake
following ablation does only lead to enhanced numbers of
activated tumour-specific T cells, when suppressive regulation is
switched off. In situ tumour destruction plus immune activation
leads to a more potent systemic anti-tumour response than either
treatment modality alone. This treatment regimen allows for direct
antigen loading of DC in vivo without delivery of defined tumour
antigens as in conventional DC vaccination.
DISCUSSION
Ex vivo generated mature DC have been shown to evoke tumour-
specific responses in cancer patients (Figdor et al, 2004; Rosenberg
et al, 2004). Dendritic cells vaccination is, however, time
consuming and expensive, and in many cases the anti-tumour
response falls short in strength to cure patients with established
tumours. Herein, we report that tumour debris created by
radiofrequency and cryo ablation comprises an effective antigen
source for DC. Moreover, we show that tumour ablation could be
efficiently combined with immune modulating approaches. This
creates an effective ‘in situ DC-vaccine’ capable of inducing
protection against lethal tumour re-challenges.
In situ tumour destruction with cryo, radiofrequency or laser
ablation has received increasing attention as a treatment modality
for focal cancer (Ruers et al, 2001; Ruers and Bleichrodt, 2002;
Curley, 2003; Erce and Parks, 2003; Veth et al, 2005). However,
little is known regarding the induction of immune responses after
in situ tumour destruction or the fate of the generated tumour
debris. In our experiments we applied a mouse B16 tumour model,
in which ex vivo generated DC vaccines are mostly only effective in
a prophylactic setting. Applying two types of ablation techniques
and different types and labelled model antigens, we now
demonstrated that antigen remaining in situ after tumour
destruction creates an effective antigen depot for the induction
of therapeutic anti-tumour immunity by DC. We applied two
distinct exogenous antigens (OVA and KLH) and two different
approaches (radioactive and fluorescent labelling) to monitor the
fate of antigens. Although it remains difficult to exclude that these
model antigens do not behave like tumour debris in all
facets, based on our as well as published results it is reasonable
to assume that they provide relevant information regarding the
flow of tumour debris (Itano et al, 2003). We showed that the
majority of antigens remained at the ablated site and that very little
antigen spreading was observed except to the draining LN. Within
the draining LN, a large percentage of DC acquired antigen as soon
as 1 day and for at least 3 days following ablation. The in vivo
loading of DC upon cryo ablation was significantly more efficient
than with radiofrequency ablation (Figures 2 and 3). The exact
nature of this difference remains to be elucidated but is likely
related to the kind of antigens that are created by the ablation and/
or to the endogenous signals that are produced upon tumour
destruction.
Our results do not provide answers on how exactly DC acquire
their antigens. It is, for instance, not known whether DC travel to
the tumour and take up the antigens locally, or that the antigen
floats to the LN via lymphatics, where LN resident DC engulf this
material. According to a recent study demonstrating LN-DC that
accumulated antigen deposited in s.c. tissue (Itano et al, 2003),
both options might be occurring at the same time. The authors
showed that antigen was first detected in LN-residing DC, followed
by a second wave of antigen-positive DC that migrated from the
periphery into the LN. Both waves were required for efficient
immune response induction and were dependent on the presence
of the challenge site. Our finding that both at day 1 and day 3
after ablation antigen-loaded DC could be discerned from the LN
suggests that similar dynamics take place in our model. In
this context, it is interesting to note that antigen loading in tumour
bearing control mice seemed to decline in these 3 days (see also
Figure 2D). Furthermore, we observed that antigens from
the tumour depot preferentially accumulate in DC, but not in B-
cells or macrophages (not shown). The basis for the observed
antigen accumulation in DC remains to be studied in more detail,
but is likely related to their strategic location within the LN and
their ability to retain antigens within their endocytotic compart-
ment, whereas macrophages rapidly degrade antigens in their
lysosomes.
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Figure 4 Ablation induces maturation of antigen-positive DC. OVA-Alexa488-positive or -negative CD11c(þ) cells (A), or GFP-positive or negative
CD11c(þ) cells (B), obtained in the experiments shown in Figure 3, were analysed separately for expression of the maturation marker CD80. Values
indicated are mean MFI’s with s.d. from three independent experiments. *¼Po0.005, **¼Po0.05 both vs no ablation.
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sThe primary goal of conventional DC-based vaccination is to
obtain tumour antigen-loaded DC in the draining LNs that are
properly activated so that they do initiate immune responses.
Although the nature of the antigens brought to the LN by DC
loaded via ablation vs antigen-positive DC from a conventional DC
vaccine is difficult to compare, we could demonstrate that far more
antigen-loaded DC were present in the draining LNs when
radiofrequency or cryo ablation was performed (Figure 3). More-
over, both ablation procedures were able to significantly increase
the absolute number of DC per LN, whereas vaccination was less
able to do so (Figure 3C). Analysis of the maturation state of
antigen-loaded and -unloaded DC in naı ¨ve, tumour-bearing and
tumour-ablated mice revealed two interesting phenomena. First,
DC that contained antigen expressed significantly higher levels of
co-stimulatory molecules than antigen negative DC. These data are
in line with in vitro data indicating that antigen uptake can affect
DC activation (Randolph et al, 1998). Second, ablation resulted in a
significant further increase in co-stimulatory molecule expression
on antigen positive, but not antigen-negative DC. We note that
neither antibodies present after positive MACS sorting, nor TLR
ligands often present in OVA batches (Pasare and Medzhitov,
2004) did bias the CD80 staining on DC, as DC purified by negative
selection showed similar results and OVA-Alexa did not mature
DC in vitro (not shown). The exact nature of these ablation-
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Figure 5 Anti-CTLA-4 improves therapeutic outcome of ablation. 0, 3 and 6 days after ablation of B16-OVA tumours, mice were injected i.p. with 200mg
anti-CTLA-4 antibodies or control IgG. (A) Forty days following ablation of tumour-bearing mice receiving antibodies, a tumour re-challenge was performed
as described before. Figures depict survival curves demonstrating growth reduction/protection after ablation plus CTLA-4 treatment. As a control, tumour
growth was monitored by injection of the same tumour dose into naı ¨ve mice (dotted lines). T¼0 corresponds to the time of injection of the tumour re-
challenge. Po0.05 for CTLA-4 vs IgG in both cryo and RF figures. One out of three representative experiments is shown (n¼5–11). (B) Control
experiment showing that CTLA-4 treatment by itself is insufficient to eradicate the primary tumour or re-challenges. Mice with established B16OVA tumours
(5–7mm) were injected with 200mg anti-CTLA-4 antibodies at days 10, 13 or 16 after tumour inoculation (solid line, arrows) or PBS (dotted line). Next,
tumour growth was monitored in time (left panel). CTLA-4 treatment or PBS given 40 days before a B16OVA challenge (15 10
3 cells) did not affect
survival of the mice (right panel). (C) At day 10 after ablation, a mix of LN and spleen cells was obtained from mice treated as indicated. T cells were
harvested from spleen and LN and restimulated with irradiated, IFN-g-treated B16-OVA cells and IL-2 for 10 days, followed by staining with OVA tetramers
(K
b) and anti-CD8b. Depicted numbers represent the percentages of tetramer-positive cells within the CD8bþ population. (D) T cells from the same bulk
cultures were used for restimulation with B16OVA cells. Supernatant from these cultures was harvested 24h later and analysed for IFN-g content by
standard ELISA methods. Shown are means with s.d. from triplicates, *¼Po0.05 vs IgG. Experiments shown in figures (B–D) were repeated twice with
comparable results.
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sdependent signals need further clarification, but may well
represent cytokines or other endogenous mediators released after
ablation (de Jong et al, 2001; Huang et al, 2002; Pasare and
Medzhitov, 2004; Sporri and Reis e Sousa, 2005). It has, for
instance, been shown that heat shock proteins and uric
acid are present in cell debris, which both influence DC and
other parts of the immune system (Somersan et al, 2001; Shi
et al, 2003). Importantly, the observed ablation-induced increase
in the number and maturation state of antigen-loaded DC is
apparently not sufficient to induce complete tumour protection
of mice.
Combination of ablation with in vivo immune modulation by
either blockade of CTLA-4 signalling or depletion of regulatory T
cells was shown to have beneficial effects in our re-challenge
model. In both cases it provided a further delay in tumour growth
compared to ablation alone. Importantly, only when CTLA-4
blockade or regulatory T-cell depletion were performed together
with ablation, significant amounts of active OVA-specific T cells
could be observed. It will be interesting to investigate the nature of
the signals resulting in DC maturation and subsequent T-cell
expansion, and the possible effects of CTLA-4 blockade or Treg
depletion on this. Moreover, possible future research can aim on
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Figure 6 Depletion of regulatory T cells improves therapeutic outcome of ablation. Four days before ablation of B16-OVA tumours, mice were injected
i.p. with 200mg anti-CD25 antibodies or control IgG. (A) Forty days following ablation of tumour-bearing mice receiving antibodies, a tumour re-challenge
was performed as described before. Figures depict survival curves demonstrating growth reduction/protection after ablation plus Treg depletion. As a
control, tumour growth was monitored by injection of the same tumour dose into naı ¨ve mice (dotted lines). T¼0 corresponds to the time of injection of
the tumour re-challenge. Po0.05 for aCD25 vs IgG in both cryo and RF figures. One out of three representative experiments is shown (n¼5–9). (B)
Control experiment showing that Treg depletion by itself is insufficient to eradicate the primary tumour or re-challenges. Mice with established B16OVA
tumours (5–7mm) were injected with 200mg anti-CD25 antibodies (solid line, arrow) or PBS (dotted line). Next, tumour growth was monitored in time
(left panel). Treg depletion or PBS given 40 days before a B16OVA challenge (15 10
3 cells) did not affect survival of the mice (right panel). (C) At day 10
after ablation, a mix of LN and spleen cells was obtained from mice treated as indicated. T cells were harvested from spleen and LN and restimulated with
irradiated, IFN-g-treated B16-OVA cells and IL-2 for 10 days, followed by staining with OVA tetramers (K
b) and anti-CD8b. Depicted numbers represent
the percentages of tetramer-positive cells within the CD8bþ population. (D) T cells from the same bulk cultures were used for restimulation with B16OVA
cells. Supernatant from these cultures was harvested 24h later and analysed for IFN-g content by standard ELISA methods. Shown are means with s.d. from
triplicates, *¼Po0.05 vs IgG. Experiments shown in figures (B–D), were repeated twice with comparable results.
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scombination of CTLA-4 blockade and Treg depletion. It was
demonstrated in a murine tumour model that this combination
had a striking synergistic effect on tumour immunity (Sutmuller
et al, 2001).
Collectively, our data show that in vivo tumour destruction in
combination with systemic immune modulation creates a unique
and potent, ‘in situ DC-vaccine’. Although radiofrequency ablation
seems to be somewhat less efficient in loading DC compared to
cryo ablation, both techniques can be efficiently combined with
immune modulation. The fact that both ablative treatments as well
as both the immune interventions are currently applied in cancer
patients, makes this promising ‘in vivo DC vaccine’ readily
applicable in clinical settings.
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